Screening for gene mutations in central nervous system metastases of non-small-cell lung cancer.
作者信息
Nicoś Marcin, Krawczyk Paweł, Jarosz Bożena, Sawicki Marek, Szumiło Justyna, Trojanowski Tomasz, Milanowski Janusz
机构信息
Departments of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-954, Lublin, Poland.
Departments of Neurosurgery and Pediatric Neurosurgery, Medical University of Lublin, 20-954, Lublin, Poland.
出版信息
Brain Pathol. 2018 Mar;28(2):295-297. doi: 10.1111/bpa.12519.
Abstract
摘要
相似文献
1
Screening for gene mutations in central nervous system metastases of non-small-cell lung cancer.非小细胞肺癌中枢神经系统转移灶的基因突变筛查
Brain Pathol. 2018 Mar;28(2):295-297. doi: 10.1111/bpa.12519.
2
Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer.非小细胞肺癌中枢神经系统转移患者中MEK1基因突变筛查的灵敏方法。
Clin Transl Oncol. 2016 Oct;18(10):1039-43. doi: 10.1007/s12094-016-1483-3. Epub 2016 Feb 9.
3
Evaluation of ALK gene rearrangement in central nervous system metastases of non-small-cell lung cancer using two-step RT-PCR technique.应用两步反转录 PCR 技术检测非小细胞肺癌中枢神经系统转移中 ALK 基因重排。
Clin Transl Oncol. 2017 Dec;19(12):1447-1453. doi: 10.1007/s12094-017-1676-4. Epub 2017 May 22.
4
[EGFR gene detection using transbronchial lung biopsy specimens].[使用经支气管肺活检标本检测表皮生长因子受体（EGFR）基因]
Zhonghua Bing Li Xue Za Zhi. 2011 Feb;40(2):111-2.
5
Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.索拉非尼用于携带K-ras突变的晚期非小细胞肺癌患者：简要报告
J Thorac Oncol. 2010 May;5(5):719-20. doi: 10.1097/JTO.0b013e3181d86ebf.
6
Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in western Turkey.土耳其西部非小细胞肺癌患者表皮生长因子受体基因突变与临床病理特征的关系
Asian Pac J Cancer Prev. 2013;14(6):3705-9. doi: 10.7314/apjcp.2013.14.6.3705.
7
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.一线使用吉非替尼治疗携带体细胞EGFR突变的晚期非小细胞肺癌患者。
J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5.
8
Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.p53和K-ras基因的突变作为非小细胞肺癌的预后因素
Int J Oncol. 1998 Mar;12(3):553-63. doi: 10.3892/ijo.12.3.553.
9
Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.非小细胞肺癌中 MET 改变的遗传筛选和分子特征。
Clin Transl Oncol. 2018 Jul;20(7):881-888. doi: 10.1007/s12094-017-1799-7. Epub 2017 Nov 14.
10
Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.根据世界卫生组织2015年标准重新分类的一组肺大细胞癌的下一代测序
Arch Pathol Lab Med. 2016 Apr;140(4):312-7. doi: 10.5858/arpa.2015-0361-OA. Epub 2015 Oct 2.
引用本文的文献
1
Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor.转移性脑肿瘤临床病理及典型分子病理特征的单中心研究
J Pathol Transl Med. 2023 Jul;57(4):217-231. doi: 10.4132/jptm.2023.06.10. Epub 2023 Jul 11.
2
Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer.非小细胞肺癌中的表皮生长因子受体突变与脑转移
Front Oncol. 2022 Nov 15;12:912505. doi: 10.3389/fonc.2022.912505. eCollection 2022.
3
Molecular Profiles of Brain Metastases: A Focus on Heterogeneity.脑转移瘤的分子特征：聚焦异质性
Cancers (Basel). 2021 May 28;13(11):2645. doi: 10.3390/cancers13112645.
本文引用的文献
1
Cranial irradiation in patients with EGFR-mutant non-small cell lung cancer brain metastases.表皮生长因子受体突变型非小细胞肺癌脑转移患者的颅部放疗。
Transl Lung Cancer Res. 2016 Feb;5(1):134-7. doi: 10.3978/j.issn.2218-6751.2016.01.08.
2
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).常规对晚期非小细胞肺癌患者进行分子谱分析：法国胸科协作组（IFCT）进行的为期 1 年的全国性计划的结果。
Lancet. 2016 Apr 2;387(10026):1415-1426. doi: 10.1016/S0140-6736(16)00004-0. Epub 2016 Jan 15.
3
Brain metastasis: clinical characteristics, pathological findings and molecular subtyping for therapeutic implications.脑转移瘤：治疗意义的临床特征、病理发现及分子亚型分析
Brain Tumor Pathol. 2016 Jan;33(1):1-12. doi: 10.1007/s10014-015-0235-3.
4
Usage of EGFR-TKI and WBRT in NSCLC patients with brain metastases.表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）与全脑放疗（WBRT）在非小细胞肺癌脑转移患者中的应用。
Ann Palliat Med. 2013 Jul;2(3):108-10. doi: 10.3978/j.issn.2224-5820.2013.05.03.
5
Comprehensive molecular profiling of lung adenocarcinoma.肺腺癌的全面分子分析。
Nature. 2014 Jul 31;511(7511):543-50. doi: 10.1038/nature13385. Epub 2014 Jul 9.
6
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.利用肺癌致癌驱动基因的多重分析来选择靶向药物。
JAMA. 2014 May 21;311(19):1998-2006. doi: 10.1001/jama.2014.3741.
7
U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.美国食品和药物管理局批准：克唑替尼治疗间变性淋巴瘤激酶阳性的晚期或转移性非小细胞肺癌。
Clin Cancer Res. 2014 Apr 15;20(8):2029-34. doi: 10.1158/1078-0432.CCR-13-3077. Epub 2014 Feb 26.
8
EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients.77 例非小细胞肺癌脑转移患者的 EGFR、KRAS、BRAF 和 HER-2 分子状态。
Cancer Med. 2013 Jun;2(3):296-304. doi: 10.1002/cam4.82. Epub 2013 Apr 23.
9
Comprehensive genomic characterization of squamous cell lung cancers.全面基因组特征分析鳞状细胞肺癌
Nature. 2012 Sep 27;489(7417):519-25. doi: 10.1038/nature11404. Epub 2012 Sep 9.
Zotero 插件